Lu-Yao G, Nikita N, Keith SW, et al. - In order to measure the short-term outcomes of abiraterone acetate (AA) and enzalutamide (ENZ) in individuals with pre-existing cardiovascular diseases (CVDs), researchers designed a population-based retrospective study. They applied the Surveillance, Epidemiology, and End Results-Medicare–linked database to distinguish prostate cancer individuals using AA or ENZ. This study included Among eligible patients a sum of 2,845 individuals with AA and 1031 with ENZ. They found that elderly prostate cancer individuals with pre-existing CVDs experienced higher short-term mortality than otherwise similar individuals without CVDs after treatment with AA or ENZ. In addition, mortality correlated with CVDs did not depend on having received AA vs ENZ.